Reversal of haloperidol-induced motor deficits by mianserin and mesulergine in rats

Pakistan Journal of Pharmaceutical Sciences

Volumn 24, Issue 1, 2011, Pages 7-12

  Shireen, Erum ^a   Haleem, Darakhshan J ^a  

^a UNIVERSITY OF KARACHI   (Pakistan)

Author keywords

Exploratory activity; Extrapyramidal symptoms; Haloperidol; Mesulergine; Mianserin; Motor coordination

Indexed keywords

HALOPERIDOL; MESULERGINE; MIANSERIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; EXPERIMENTAL RAT; EXPLORATORY BEHAVIOR; MALE; MOTOR ACTIVITY; MOTOR COORDINATION; MOTOR DYSFUNCTION; NONHUMAN; OPEN FIELD BEHAVIOR; PARKINSONISM; RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; CATALEPSY; DOPAMINE AGONISTS; DYSKINESIA, DRUG-INDUCED; ERGOLINES; HALOPERIDOL; MALE; MIANSERIN; MOTOR ACTIVITY; PARKINSON DISEASE, SECONDARY; PSYCHOMOTOR PERFORMANCE; RATS; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONIN UPTAKE INHIBITORS;

EID: 78651407520     PISSN: 1011601X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Anderson HL and Kilpatrick IC (1996). Prevention by (+/-) 8-hydroxy-2-(di-n-propylamino) tetralin of both catalepsy and the rise in rat striatal dopamine metabolism caused by haloperidol. Br. J. Pharmacol., 118: 421-427.
2. Arnt H Hyrttel and Back-Lauriten T (1986). Futher studies of the mechanism behind scopolamine-induced reversal antistereotypic and anticataleptogenic effects of neuroleptics in rats. Acta Pharmacol. Toxicol., 69: 319-324.
3. Bligh-Glover W, Jaskiw GE, Vrtunski B, Ubogy D and Meltzer HY (1995). 5-HT-2 receptor antagonists can attenuate submaximal haloperidol-induced catalepsy in rats. Schizophr Res., 15: 153-154.
4. Bonhomme LG, Dedeurwaerdere P, Lemoal M and Spampinato U (1997). 8-OH-DPAT, a 5-HT-1A agonist and ritanserin, a 5-HT-2A/2C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal DA release. Psychopharmacology, 131: 57-63.
5. Clausing P, Gough B, Holson R.R, Slikker Jr. W and Bowyer JF (1995). Amphetamine levels in brain Microdialysis, caudate/putamen, Substantia nigra and plasma after dosage that produces either behavioral or neurotoxic effects. Journal of Pharmcol Exp. Ther., 274(2): 614-621.
6. Clemett DA, P, Punhani T, Duxon MS, Blackburns TP and Fone KC (2000). Immunohistochemical localization of the 5-HT-2C receptor protein in the rat CNS. Neuropharmacology, 39: 261-263.
7. Drew KL, William T, O'Connor WT, Kehr J and Ungerstedt U (1990). Regional specific effects of clozapine and haloperidol on GABA and DA release in the basal ganglia. Eur. J. Pharmac., 187: 385-397. (Pubitemid 20357490)
8. Esposito E (2006). Serotonin-dopamine interaction as a focus of novel antidepressant drugs. Curr. Drug Targetas, 7(2): 177-185.
9. Elliot PJ, Walsh DM, Close SP, Higgins G and Hayes AG (1990). Behavioral effects of serotonin agonists and antagonists in the rat and marmoset. Neuropharmacology, 29: 949-956. (Pubitemid 20347441)
10. Evins AE and Goff DC (1996). Adjunctive antidepressant drug therapies in the treatment of negative symptoms in schizophrenia. CNS Drugs, 6: 130-147. (Pubitemid 26272980)
11. Fillip M and Cunningham KA (2002). 5-HT-2C receptors in nucleus accumbens regulate expression of the hyperlocomotive and discriminative stimulus effects of cocaine. Pharmacol. Biochem. Behav. 71: 745-756.
12. Grinshpoon A, Valevski A, Moskowitz M and Weizman A (2000). Beneficial effect of the addition of the 5-HT- 2A/2C and alpha 2 antagonists to ongoing haloperidol treatment in drug-resistant chronically hospitalized schizophrenic patients. Eur. Psychiatry, 15: 388-390.
13. Haleem DJ (2006). Serotonergic modulation of DA neurotransmission: A mechanism for enhancing therapeutics in schizophrenia. JCPSP, 16(8): 556-562.
14. Haleem DJ, Samad N and Haleem MA (2007a). Reversal of haloperidol-induced vacuous chewing movements and supersensitive somatodendritic serotonergic response by buspirone in rats. Pharmacological Biochemistry & Behavior. 87: 115-121. (Pubitemid 46855825)
15. Haleem DJ and Shireen E and Haleem MA (2004). Somatodendritic and postsynaptic serotonin-1A receptors in the attenuation of haloperidol-induced catalepsy. Prog. in Neuro-Psychopharamacology & Biological Psychiatry, 28: 1323-1329.
16. Haleem DJ, Batool F, Khan NH, Kamil N, Ali O, Saify ZS and Haleem MA (2002a). Differences in the effects of haloperidol and clozapine on rat brain serotonin and dopamine metabolism and on tests related to extrapyramidal functions in rats. Med. Sci. Monit. 8: 3354-3361.
17. Haleem DJ and Khan NH (2003). Enhancement of serotonin-1A receptor dependent responses following withdrawal of haloperidol in rats. Prog. Neuropsychopharmacol. Biol. Psychiat., 27(4): 645-651.
18. Haleem DJ (1993). Function specific supersensitivity of m-Chlorophenyl piperazine-induced serotonergic neurotransmission in female compared to male rats. Life Sci., 52: PL279-284
19. Hicks PB (1990). The effects of serotonergic agents on haloperidol-induced catalepsy. Life Sci,. 47: 1609-1615.
20. Ikram H, Samad N and Haleem DJ (2007). Neurochemical and behavioral effects of m-cpp in a rat model of tardive dyskinesia. Pak. J. Pharm. Sci. 20(3): 185-188.
21. Jacob BL and Azmitia EC (1992). Structure and function of the brain serotonin system. Physiol. Rev., 72: 165-229.
22. Kennett GA, Whitton P, Shah K and Curzon G (1989). Anxiogenic like effects of mCpp and TFMPP animal models are opposed by 5-HT-1C receptor antagonists. Eur. J. Pharmacol., 164: 445-454. (Pubitemid 19146953)
23. Kapur S, Ramington G, Jones C, Wilson AA, DaSilva J, Houle S and Zipursky RB (1996a). High levels of dopamine D2 receptor occupancy with low dose haloperidol treatment: A PET Study. Am. J. Psychiatry, 153: 946-950.
24. Karl T, Duffy L, O'Brien E, Matsumoto I and Dedova I (2006). Behavioural effects of chronic haloperidol and risperidone treatment in rats. Behav. Brain Res., 171: 286-294. (Pubitemid 43946503)
25. Lewis DA and Liberman JA (2000). Catching upon schizophrenia: Natural history and neurobiology. Neuron, 28: 325-334.
26. McMohan LR, Filip M and Cunningham KA (2001). Differential regulation of the mesoaccumbens circuit by 5-HT-2A/2C receptors. J. Neurosci., 21: 7781-7787.
27. Mizuki Y, Kajimura N, Imai T, Suetsugi M, Kai S, Kaneyuki H and Yamada M (1990). Effects of mianserin on negative symptoms in schizophrenia. Int. Clin. Psychopharmacol., 5: 83-95.
28. Mizuki Y, Kajimura N, Kai S, Suetsugi M, Ushijima I and Yamada M (1992). Effects of mianserin in chronic schizophrenia. Prog. NeuroPsychopharamacology & Biol Psychiatry. 16: 517-528.
29. Neal-Beliveau BS, Joyce JN and Lucki I (1993). Serotonergic involvement in haloperidol-induced catalepsy. J. Pharmacol. Exp. Ther., 265: 207-217.
30. Pinder RM (1991). Mianserin: Pharmacological and clinical correlates. Nordisk Psykiatrisk Tidskrift, 45: 13-26.
31. Petry N, Fumidge L, Tong Z.Y, Martin C and Clark D (1993). Time sampling observation procedure for studying interaction between d-amphetamine and selective DA receptor in the rats. Pharmaocol Biochem Behav., 446(1): 167-80.
32. Plasky P (1991). Antidepressant usage in schizophrenia. Schizophr. Bull., 17: 649-657.
33. Pazos A, Probst A and Palacios JM (1987). Serotonin receptors in the human brain: IV Autoradiographic mapping of 5-HT-2 receptors. Neuroscience, 21: 123-129.
34. Poyorovsky M, Koren D, Gonopolsky I, Schneidman M, Fuchs C, Weizman A and Weizman R (2003). Effects of 5-HT-2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: An add on, double blind placebo-controlled study. Eur. Neuropsychopharmacol., 13: 123-128.
35. Poyorovsky M, Shardorodsky, Fuchs C, Schneidman M and Weizman A (1999). Treatment of neuroleptic-induced akathisia with 5-HT-2 antagonist mianserin: Double blind placebo-controlled study. Br. J. Psychiatry, 174: 238-242.
36. Ranjan S, Chandra PS, Chatuverdi SK, Prabhu SC and Gupta A (2006). Atypical antipsychotic induced akathisia with depression: Therapeutic role of mitrazipine. Amr. Pharmocther., 40: 771-774.
37. Reavill C, Kettle A, Holland V, Riley G and Blackburn TP (1999). Attenuation of haloperidol-induced catalepsy by 5-HT-2C receptor antagonist. Br. J. Pharmacol., 126: 572-574.
38. Saller CF, Czupryna MJ and Salama Al (1990). 5-HT-2 receptor blockade by ICI-169,369 and other 5-HT-2 antagonists modulates the effects of D-2 DA receptor blockade. J. Pharmacol. Exp. Ther., 253: 1162-1170.
39. Samad N, Haleem MA and Haleem DJ (2008). Behavioral effects of m-cpp in a rat model of tardive dyskinesia. Pak. J. Pharm.Sci., 21(3): 262-268.
40. Shiloh R, Zemishlany Z, Aizenberg D, Valevski A, Bodinger L, Munitz H and Weizman A (2002). Mianserin or placebo as adjuncts to typical antipsychotics in resistant schizophrenia. Int. Clin. Psychopharmacol., 17: 59-64.
41. Stryjer R, Grupper D, Strous R, Poyrovsky M and Weizman A (2004). Mianserin for the rapid improvement of chronic akathisia in schizophrenia patient. Eur. Psychiatry, 19: 237-238.
42. Thomas GM, Gittins SA, Collin LL et al. (1998). Functional characterization of the human cloned 5-HT- 7 receptor: Antagonist profile of SB-258719. Br. J. Pharmacol., 124: 1300-1306.
43. Wadenberg MG, Browning JL, Young KA and Hicks PB (2001). Antagonism at 5-Ht-2A receptors potentiates the effects in a conditioned avoidance response task in rats. Pharm. Beh. & Biochem., 68: 363-370.
44. Wadenberg M (1996). Serotonergic mechanism in neuroleptic-induced catalepsy in rats. Neuroscience and Biobehioral Reviews, 20(2): 325-339.
45. Walting KJ, Kenabian JW and Niewmeyer JL (1995). The RBI handbook of receptor classification of and signal transduction. Res. Biochem. Int., 110-117.
46. Zoccali R, Muscatello MR, Torre DL, Malara G, Canale A and Crucitti D et al. (2003). Lack of pharmacokinetic interaction between mitrazipine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia. Pharmacological Res., 48: 411-414.